Pharsight

Drugs that contain Tadalafil

1. Adcirca patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5859006 ELI LILLY CO Tetracyclic derivatives; process of preparation and use
Nov, 2017

(6 years ago)

US5859006

(Pediatric)

ELI LILLY CO Tetracyclic derivatives; process of preparation and use
May, 2018

(6 years ago)

US7182958 ELI LILLY CO β-carboline pharmaceutical compositions
Apr, 2020

(4 years ago)

US7182958

(Pediatric)

ELI LILLY CO β-carboline pharmaceutical compositions
Oct, 2020

(3 years ago)

US6821975 ELI LILLY CO Beta-carboline drug products
Nov, 2020

(3 years ago)

US6821975

(Pediatric)

ELI LILLY CO Beta-carboline drug products
May, 2021

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 22, 2012
Orphan Drug Exclusivity(ODE) May 22, 2016

Market Authorisation Date: 22 May, 2009

Treatment: Treatment of pulmonary hypertension

Dosage: TABLET;ORAL

How can I launch a generic of ADCIRCA before it's drug patent expiration?
More Information on Dosage

ADCIRCA family patents

Family Patents

2. Cialis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6140329 LILLY Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence
Jul, 2016

(7 years ago)

US5859006 LILLY Tetracyclic derivatives; process of preparation and use
Nov, 2017

(6 years ago)

US5859006

(Pediatric)

LILLY Tetracyclic derivatives; process of preparation and use
May, 2018

(6 years ago)

US7182958 LILLY β-carboline pharmaceutical compositions
Apr, 2020

(4 years ago)

US6943166 LILLY Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
Apr, 2020

(4 years ago)

US6943166

(Pediatric)

LILLY Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
Oct, 2020

(3 years ago)

US7182958

(Pediatric)

LILLY β-carboline pharmaceutical compositions
Oct, 2020

(3 years ago)

US6821975 LILLY Beta-carboline drug products
Nov, 2020

(3 years ago)

US6821975

(Pediatric)

LILLY Beta-carboline drug products
May, 2021

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-219) Feb 15, 2021
Pediatric Exclusivity(PED) Aug 15, 2021
New Indication(I-642) Oct 06, 2014
New Indication(I-641) Oct 06, 2014

Market Authorisation Date: 07 January, 2008

Treatment: Treatment of erectile dysfunction; Treatment of sexual dysfunction

Dosage: TABLET;ORAL

How can I launch a generic of CIALIS before it's drug patent expiration?
More Information on Dosage

CIALIS family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Tadliq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11666576 CMP DEV LLC Liquid oral formulations for tadalafil
Dec, 2038

(14 years from now)

US11382917 CMP DEV LLC Liquid oral formulations for tadalafil
Dec, 2038

(14 years from now)

Market Authorisation Date: 17 June, 2022

Treatment: Tadliq is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability

Dosage: SUSPENSION;ORAL

More Information on Dosage

TADLIQ family patents

Family Patents